U.S. pharma big copyright scrapped two experimental weight loss supplements final 12 months—a once-day-to-day tablet, lotiglipron, due to elevated liver enzymes plus a two times-daily pill, danuglipron, resulting from sturdy Unwanted side effects—but CEO Albert Bourla has said the company is set to “Enjoy and win” within the obesity Area an